STALLERGENES GREER ETABLERER SIG PÅ DET DANSKE, NORSKE OG SVENSKE MARKED
Stallergenes Greer, et globalt førende selskab inden for allergen immunterapi (AIT), er glade for at kunne meddele, at vi har etableret et datterselskab dedikeret til det danske, norske og svenske marked. Stallergenes Greer Danmark ApS tilbyder sundhedsvæsenet og patienter en fuldt registreret portefølje af sublinguale tabletbehandlinger til græspollen og husstøvmide-induceret allergisk rhinitis.
I Europa rammer allergisk rhinitis 1 ud af 5 personer (en forekomst på 19 %)1, en andel der har været stigende i løbet af de seneste årtier. Det er for det meste forårsaget af luftbårne allergener såsom pollen eller husstøvmider, der udløser symptomer i næse og øjne, der kan forringe dagligdagen og muligvis føre til udvikling af allergisk astma - en kronisk og invaliderende tilstand, der påvirker 15% til 38% af patienter med allergisk rhinitis2.
”Vi er glade for at kunne etablere os i Norden og bidrage til at forbedre livskvaliteten for patienter med græspollen- og husstøvmideallergi. Med etableringen af Stallergenes Greer Danmark ApS kan allergikere og læger i Danmark, Norge og Sverige regne med Stallergenes Greers dedikation ved at levere effektive, højkvalitets og klinisk dokumenterede allergenimmunterapibehandlinger”, siger Brice Chouquet, direktør for Stallergenes Greer Norden. Finland følger efter i 2025.
Udvidelsen af Stallergenes Greers geografiske tilstedeværelse i Norden er et vidnesbyrd om koncernens forpligtelse til at give patienter og sundhedspersonale over hele verden omfattende allergibehandling. Med næsten 120 års ekspertise inden for allergi og allergen immunterapi (AIT) har Stallergenes Greer en omfattende global tilstedeværelse og betydelig kapacitet til fremstilling af allergen og færdige AIT-produkter. Stallergenes Greers innovative behandlinger bygger på en langvarig ekspertise inden for allergenimmunterapi og er udviklet til at imødekomme allergikeres specifikke behov.
OM STALLERGENES GREER DANMARK APS
Stallergenes Greer Danmark ApS er et datterselskab af Stallergenes Greer AG, en global sundhedsvirksomhed baseret i Baar, Schweiz, med speciale i diagnosticering og behandling af luftvejs-, fødevare- og insektallergier gennem udvikling og kommercialisering af allergenimmunterapiprodukter og -tjenester. Stallergenes Greer International AG er moderselskab for Greer Laboratories, Inc. (registreret i USA) og Stallergenes SAS (registreret i Frankrig). For mere information, besøg www.stallergenesgreer.com.
- Savouré et al., Worldwide prevalence of rhinitis in adults: A review of definitions and temporal evolution, Clin and Translat Allergy 2022 Vol. 12 Issue 3, article e12130.
- Brozek et al., Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016, revision J Allergy Clin Immunol 2017 Vol. 140 Issue 4 Pages 950-958.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20241024630549/da/
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
New Study from UK’s Largest Virtual ADHD Service Validates Role of Objective Testing in Delivering Personalized, High-Quality Remote ADHD Care10.5.2025 12:45:00 CEST | Press release
Data presented at ADHD World Congress highlights how QbCheck supports diagnostic accuracy and individualized treatment monitoring, enabling efficient and robust care in virtual settings. News Summary: New findings show significant improvements in access, clinician confidence, symptom tracking, and individualized care using objective testing. The study underscores the importance of scalable, evidence-based tools, as many countries, including both the UK and the US, face rising demand for ADHD diagnosis and treatment. The study revealed significant improvements post-treatment, validating clinical practice and better clinician-patient alignment. As demand for virtual ADHD care increases, findings from a new study conducted with ADHD 360, the UK’s largest evidence-based digital service specializing in ADHD diagnosis and treatment, reveal how objective ADHD diagnostic and monitoring technology improves patient outcomes and clinical certainty. Presented at the 2025 ADHD World Congress in Pra
Ant International Partners with Barclays on Global Treasury Management with Proprietary AI-Powered FX Model9.5.2025 15:57:00 CEST | Press release
The Time-Series Transformer AI FX Model forecasts cashflow and FX exposure with more than 90% accuracy, helping businesses reduce FX-related fees Ant International has entered a partnership with leading UK bank Barclays to enhance efficiency and resilience in global treasury management for businesses. Under the partnership, the two sides will combine innovative solutions, including Ant’s proprietary Time-Series Transformer (TST) AI FX Model, to help businesses reduce FX-related costs and risks against global volatilities. At the initial stage of the collaboration, Ant International has successfully completed the first batch of its intra-group FX transactions with Barclays. Ant International’s TST Model is a transformer architecture-based big data model with close to 2 billion parameters. By integrating the latest time series forecasting algorithms, the TST Model predicts patterns over time. Ant also created new pre-training and Supervised Fine-Tuning (SFT) frameworks to train the model
IFF Completes Divestiture of Nitrocellulose Business9.5.2025 14:00:00 CEST | Press release
IFF (NYSE: IFF) today announced that it has completed the divestiture of its nitrocellulose business, including Walsrode Industrial Park in lower Saxony, Germany, to Czechoslovak Group (CSG). The business manufactures nitrocellulose strictly for industrial purposes, serving customers primarily in coatings and printing inks, and had been part of IFF’s Pharma Solutions business unit. “The divestiture of our nitrocellulose business builds upon our deleveraging journey and enables us to focus on our core businesses,” said Erik Fyrwald, IFF CEO. “I’d like to thank our nitrocellulose colleagues for their dedication and wish them continued success as part of CSG.” Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Le
Monument Re Transfers €1.4bn Greycastle Portfolio to RGA and Strengthens European Life Insurance Consolidation Platform9.5.2025 14:00:00 CEST | Press release
Monument Re Limited (“Monument”) announces today that it has transferred a legacy €1.4bn reinsurance portfolio, comprising annuity and other life insurance liabilities acquired as part of the 2020 Greycastle transaction, to RGA Americas Reinsurance Company, Ltd. (“RGA”). This transaction releases capital resources that Monument will redirect to its core strategy of consolidation in European life insurance markets. The transaction completed on 2May 2025 following approval by the Boards of Directors of both Monument and RGA and non-objection from the Bermuda Monetary Authority. Monument has taken significant steps in recent months to strengthen its business operations by consolidating its European group support functions in Dublin and by aligning with the recently strengthened regulatory regime in Bermuda. With its strong financial position and best in class capabilities in the Group, Monument remains ideally positioned to build on its success to date and grow its European footprint, del
CPAC Systems AB Announces Strategic Minority Investment in Flying Fish9.5.2025 12:33:00 CEST | Press release
Accelerating the shift toward sustainable and intelligent water mobility CPAC Systems AB, a leader in advanced control systems and embedded vessel and commercial vehicle technology, today announced a strategic minority investment in Flying Fish Maritime Innovations B.V., a pioneer in advanced shared water mobility solutions and robust, cost-effective hydrofoil technology. The investment underscores both companies’ commitment to redefining water-based transportation through innovation, sustainability, and seamless integration. It marks the beginning of a deeper collaboration aimed at enabling smarter, cleaner, and more connected mobility on the water — for both recreational and commercial applications. “We are thrilled to support Flying Fish and their impressive work in redefining water mobility,"saidMarcus Wingolf, CEO of CPAC Systems. "Our investment in Flying Fish represents a strategic alignment of our technical proficiencies and innovative ambitions. This partnership opens exciting
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum